Last reviewed · How we verify
Ginkgo biloba & Methylprednisolone
Ginkgo biloba & Methylprednisolone is a Combination therapy: herbal antioxidant + corticosteroid Small molecule drug developed by Asan Medical Center. It is currently in Phase 3 development for Acute spinal cord injury (Phase 3 trial context at Asan Medical Center). Also known as: Ginexin, Methylprednisolone.
This combination uses Ginkgo biloba's antioxidant and neuroprotective properties alongside methylprednisolone's anti-inflammatory and immunosuppressive effects to reduce neuroinflammation and promote recovery.
This combination uses Ginkgo biloba's antioxidant and neuroprotective properties alongside methylprednisolone's anti-inflammatory and immunosuppressive effects to reduce neuroinflammation and promote recovery. Used for Acute spinal cord injury (Phase 3 trial context at Asan Medical Center).
At a glance
| Generic name | Ginkgo biloba & Methylprednisolone |
|---|---|
| Also known as | Ginexin, Methylprednisolone |
| Sponsor | Asan Medical Center |
| Drug class | Combination therapy: herbal antioxidant + corticosteroid |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Ginkgo biloba contains flavonoids and terpenoids that scavenge free radicals and improve microcirculation, while methylprednisolone is a corticosteroid that suppresses inflammatory cytokine production and reduces edema. Together, they target both oxidative stress and inflammatory pathways implicated in acute neurological injury or degeneration.
Approved indications
- Acute spinal cord injury (Phase 3 trial context at Asan Medical Center)
Common side effects
- Hyperglycemia
- Infection risk (immunosuppression)
- Gastrointestinal upset
- Insomnia
- Mood changes
Key clinical trials
- The Effect of PAP on ISSHL Comorbided With OSA (PHASE4)
- The Efficacy of Steroid Therapy in Vestibular Neuritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ginkgo biloba & Methylprednisolone CI brief — competitive landscape report
- Ginkgo biloba & Methylprednisolone updates RSS · CI watch RSS
- Asan Medical Center portfolio CI
Frequently asked questions about Ginkgo biloba & Methylprednisolone
What is Ginkgo biloba & Methylprednisolone?
How does Ginkgo biloba & Methylprednisolone work?
What is Ginkgo biloba & Methylprednisolone used for?
Who makes Ginkgo biloba & Methylprednisolone?
Is Ginkgo biloba & Methylprednisolone also known as anything else?
What drug class is Ginkgo biloba & Methylprednisolone in?
What development phase is Ginkgo biloba & Methylprednisolone in?
What are the side effects of Ginkgo biloba & Methylprednisolone?
Related
- Drug class: All Combination therapy: herbal antioxidant + corticosteroid drugs
- Manufacturer: Asan Medical Center — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Acute spinal cord injury (Phase 3 trial context at Asan Medical Center)
- Also known as: Ginexin, Methylprednisolone
- Compare: Ginkgo biloba & Methylprednisolone vs similar drugs
- Pricing: Ginkgo biloba & Methylprednisolone cost, discount & access